EP2613790A1 - Laxatif contenant du polyéthylène glycol et au moins un électrolyte - Google Patents

Laxatif contenant du polyéthylène glycol et au moins un électrolyte

Info

Publication number
EP2613790A1
EP2613790A1 EP11760729.1A EP11760729A EP2613790A1 EP 2613790 A1 EP2613790 A1 EP 2613790A1 EP 11760729 A EP11760729 A EP 11760729A EP 2613790 A1 EP2613790 A1 EP 2613790A1
Authority
EP
European Patent Office
Prior art keywords
medical device
component
polyethylene glycol
container
electrolyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11760729.1A
Other languages
German (de)
English (en)
Inventor
Detlef Schierstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHIERSTEDT, DETLEF
Original Assignee
Krewel Meuselbach GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krewel Meuselbach GmbH filed Critical Krewel Meuselbach GmbH
Publication of EP2613790A1 publication Critical patent/EP2613790A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a polyethylene glycol (PEG) -based laxative having improved compliance.
  • a medical device according to the invention is suitable for the treatment of chronic constipation.
  • Constipation is the delayed discharge of dry and hard stools. It can either be attributed to a slowed intestinal passage or a disturbed discharge reflex.
  • the causes of delayed intestinal transit include dietary factors, changes in the intestinal wall, endocrine disorders and functional and organic disorders of the nervous system.
  • Drugs, such as sedatives, psychotropic drugs or opioids may also have an obstipating effect.
  • a disturbed evacuation reflex can be found in diseases of the anal canal, loss of the rectal stretch reflex or weakness of the abdominal press.
  • laxatives are used for a short time to accelerate defecation. Most laxatives work by increasing the intraluminal volume and thus by increasing the internal pressure in the lumen Intestinal trigger peristaltic waves. Basically, one can distinguish here three groups of laxatives, which have such an effect:
  • Naturally occurring or synthetically produced swellable, non-digestible polysaccharides such as, for example, flaxseed or Indian psyllium, which swell up in the intestine, are suitable as mild laxatives. These must be taken together with sufficient water to avoid gelatinisation of the intestinal contents.
  • the well-known castor oil inhibits sodium ion and water absorption by blocking the sodium ion / potassium ion-dependent ATPase. The laxative effect is reliable. Since it is not taken with pleasure, it is more suitable for therapy of acute constipation.
  • Polyethylene glycol a polymeric powder
  • the powder binds the water with which it is taken and transports it into the large intestine. There, the osmotic pressure is increased locally and water is released into the intestinal lumen.
  • Polyethylengiykol is neither absorbed nor methabolized (Mutschier drug effects: Textbook of Pharmacology and Toxicology by E. Mutschier et al., 8th edition, Stuttgart: Stuttgart Verlagsgesellschaft mbH, 2001, pp. 647-652),
  • the object of the present invention is thus to provide a product for the treatment of chronic constipation with improved compliance.
  • the essence of the invention is that you can significantly improve the compliance, if polyethylene glycol and electrolyte are taken separately.
  • the object underlying the present invention is achieved by a medical device for the treatment of chronic constipation, which is characterized in that it comprises two spatially separated components A and B, wherein component A is a polyethylene glycol (PEG) and component B at least comprises an electrolyte.
  • a medical device for the treatment of chronic constipation which is characterized in that it comprises two spatially separated components A and B, wherein component A is a polyethylene glycol (PEG) and component B at least comprises an electrolyte.
  • component A is a polyethylene glycol (PEG)
  • component B at least comprises an electrolyte.
  • the polyethylene glycol preferably has a molecular weight in the range from 2000 g / mol to 6000 g / mol, in particular in the range of 3000 g / mol to 4000 g / mol, in particular of 3350 g / mol.
  • Corresponding polyethylene glycols have a particularly good osmotic action in the intestine, which is predominantly responsible for the effect of laxity. For example, a certain amount of PEG 2000 (polyethylene glycol having a molecular weight of 2000 g / mol) causes an approximately twice as high osmotic pressure as the same amount of PEG 4000 (polyethylene glycol having a molecular weight of 4000 g / mol).
  • the PEG has a bitter taste. This results in a deteriorated compliance. If the molecular weight of the PEG is too large, the osmotic effect is too low. A sufficient laxative effect is not achieved here.
  • the daily dose is usually in the range of 7g to 40g, preferably 13g to 26g, PEG per day. With a supplied amount of less than 7g PEG per day, a sufficient laxative effect can not be ensured. If the amount of ingested PEG is significantly more than 40g per day, it can cause diarrhea. Intake of 13g to 26g PEG per day has been found to be the most preferred dose in adults. However, this value is dependent on individual conditions, such as body weight or cause of constipation.
  • the medical device according to the invention in ingredient A has 13.125 g of PEG as a single dose. This corresponds to a daily standard dose for one Adults. If the need is greater, up to three single doses can be taken each day.
  • constituent A may additionally comprise one or more flavoring agents which additionally improve compliance.
  • flavors are understood to be flavors such as, for example, orange flavors or acidulants, such as, for example, citric acid.
  • ingredient A may also comprise sweeteners such as saccharin-Na, sugar and / or Na-cyclamate, etc.
  • the contained PEG itself is almost tasteless.
  • the inventive addition of flavor and / or sweetener gives a pleasant taste of the medical device. By varying these substances you can adjust the intensity of the aroma and sweetness. Due to the pleasant taste, even after prolonged ingestion no aversion to the medical device according to the invention develops, which leads to a significantly improved compliance even over a longer period of administration.
  • Component A is present in an embodiment according to the invention as granules, in particular as drinking granules for dissolution, or as finished solution.
  • the medical device according to the invention furthermore comprises at least one electrolyte. This is spatially separated as part B before.
  • electrolyte for example, NaCl and / or KCl, and, optionally, sodium bicarbonate may additionally be used.
  • Mg.sup. + Salts and / or Ca.sup. Salts for example as citrate, and / or optionally in addition, may furthermore be added.
  • the constituent B comprising the electrolyte can be present, for example, in the form of a coated granule or powder, as a tablet, film-coated tablet, capsule and / or dragee.
  • component B is present as a film tablet.
  • the auxiliaries customary for this purpose can be used.
  • the object underlying the present invention is achieved by a combination pack comprising at least two separate containers, wherein in one container 1 component A of the medical device and in another container 2 component B of the medical product is included.
  • Container 1 may be a bag according to the invention. In particular bags of coated aluminum are used here. Such a bag is suitable both for receiving the polyethylene glycol-containing granules or the finished drink solution. The drink solution can also be bottled for single and / or multiple use.
  • the component B containing the electrolyte is preferably in solid form.
  • An appropriate container 2 can thus be a bag and / or a deep-drawn film.
  • the electrolyte tablets according to the invention can thus be present, for example, as a biostrap.
  • the container 1 and the container 2 can also be separably connected to one another.
  • the separation of the two containers from each other must be such that the respective containers 1 and 2 remain intact. This can be done for example by means of a perforation.
  • components A and B must not mix with each other.
  • Example 1 The separate intake of components A and B ensures a significant improvement in compliance. This also lasts for a longer period. It also ensures the supply of the required electrolytes. Exemplary embodiments: Example 1
  • Component A Granules:
  • Component B Tablet:
  • Component A Solution in aluminum bag:
  • Citric acid 0.131 g Component B Tablet:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne un laxatif contenant du polyéthylène glycol (PEG) ayant une adhésion améliorée. Un produit médicinal selon l'invention convient au traitement de la constipation chronique et est caractérisé en ce qu'il contient deux constituants A et B présents séparément dans l'espace, le constituant A contenant du polyéthylène glycol (PEG) et le constituant B contenant au moins un électrolyte
EP11760729.1A 2010-09-07 2011-09-01 Laxatif contenant du polyéthylène glycol et au moins un électrolyte Withdrawn EP2613790A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE202010012256U DE202010012256U1 (de) 2010-09-07 2010-09-07 Abführmittel
PCT/EP2011/065131 WO2012031978A1 (fr) 2010-09-07 2011-09-01 Laxatif contenant du polyéthylène glycol et au moins un électrolyte

Publications (1)

Publication Number Publication Date
EP2613790A1 true EP2613790A1 (fr) 2013-07-17

Family

ID=43070368

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11760729.1A Withdrawn EP2613790A1 (fr) 2010-09-07 2011-09-01 Laxatif contenant du polyéthylène glycol et au moins un électrolyte

Country Status (7)

Country Link
US (1) US20130171255A1 (fr)
EP (1) EP2613790A1 (fr)
JP (1) JP2013540726A (fr)
CN (1) CN103079575A (fr)
DE (1) DE202010012256U1 (fr)
EA (1) EA201390350A1 (fr)
WO (1) WO2012031978A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016226380A1 (en) * 2015-03-02 2017-09-21 Colonaryconcepts Llc Compounds and methods for PEG metabolite and PEG breakdown product assays
FR3056109B1 (fr) * 2016-09-21 2019-10-11 Pierre Fabre Medicament Utilisation de formulations solides de polyethylene glycol dans le traitement de la constipation
CN107028876B (zh) * 2016-10-09 2020-09-29 舒泰神（北京）生物制药股份有限公司 聚乙二醇电解质口服液及其制备方法
CN110433174A (zh) * 2019-07-17 2019-11-12 华南理工大学 一种高依从性的复方聚乙二醇电解质散剂及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123901A1 (fr) * 2009-04-21 2010-10-28 Bachwich Dale R Système de lavage du côlon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409104D0 (en) * 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123901A1 (fr) * 2009-04-21 2010-10-28 Bachwich Dale R Système de lavage du côlon

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Moviprep (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic acid for Oral solution)", INTERNET CITATION, 2006, pages 1 - 7, XP002716678, Retrieved from the Internet <URL:http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021881lbl.pdf> [retrieved on 20131120] *
See also references of WO2012031978A1 *

Also Published As

Publication number Publication date
EA201390350A1 (ru) 2013-07-30
WO2012031978A1 (fr) 2012-03-15
US20130171255A1 (en) 2013-07-04
CN103079575A (zh) 2013-05-01
JP2013540726A (ja) 2013-11-07
DE202010012256U1 (de) 2010-11-11

Similar Documents

Publication Publication Date Title
EP2635264B1 (fr) Formulations comportant du polyéthylène glycol
DE4244588A1 (fr)
WO2018024887A1 (fr) Composition pour traiter la veisalgie
WO2012031978A1 (fr) Laxatif contenant du polyéthylène glycol et au moins un électrolyte
DE3927723A1 (de) N - acetylglucosamin zur buccalen anwendung
WO2009036906A1 (fr) Composition avec combinaison de principes actifs constituée d&#39;un laxatif et d&#39;un agent antimoussant, pour le traitement de la constipation
WO2006089317A1 (fr) Forme posologique de presentation pharmaceutique agissant sur la microcirculation et contenant au moins un flavonoide
EP3737246A1 (fr) Complément alimentaire, ses utilisations, procédé de supplémentation alimentaire et spray buccal
CN104958254A (zh) 一种盐酸多奈哌齐口服溶液及其制备方法
WO2001054676A2 (fr) Formulations destinees a des etats de deshydratation
EP1150660B1 (fr) Formulation effervescente pharmaceutique contenant du metamizol
CN110179860A (zh) 一种抗癫痫的药物、其制备方法及用途
JP6122244B2 (ja) 集中力持続性を向上させる作用を有する組成物
DE2743702A1 (de) Abmagerungs- oder schlankmacher- zubereitung und verfahren zu ihrer herstellung
CH698926B1 (de) Pulverförmiges Vitamin C-Zink-Präparat zur oralen Verabreichung
DE202023103619U1 (de) Darreichungsform auf Basis von Pflanzenextrakten
CH712787A2 (de) Zusammensetzung zur Behandlung von Veisalgia.
AT12928U1 (de) Formulierungen
CN104161764B (zh) 含有苦参素和甘草酸的药物组合物制备治疗银屑病的应用
EP4297588A1 (fr) Complément alimentaire en poudre pour la préparation d&#39;une boisson
WO2021073762A1 (fr) Association médicamenteuse à usage médical pour le traitement d&#39;une maladie due à une lésion des fonctions tubulaires rénales
CN118892447A (zh) 一种舍曲林口服浓缩液体组合物的制备方法
EP1462149B1 (fr) Utilisation du phenazon pour le traitement du migraine
DE202005009181U1 (de) Reizlinderndes Hustenmittel
DE102004057758A1 (de) Synergistische Arginin-Kombination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SCHIERSTEDT, DETLEF

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SCHIERSTEDT, DETLEF

17Q First examination report despatched

Effective date: 20140916

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150127